GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (FRA:82P) » Definitions » EV-to-EBITDA

Pacira BioSciences (FRA:82P) EV-to-EBITDA : 8.98 (As of May. 18, 2024)


View and export this data going back to . Start your Free Trial

What is Pacira BioSciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pacira BioSciences's enterprise value is €1,555.5 Mil. Pacira BioSciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €173.2 Mil. Therefore, Pacira BioSciences's EV-to-EBITDA for today is 8.98.

The historical rank and industry rank for Pacira BioSciences's EV-to-EBITDA or its related term are showing as below:

FRA:82P' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1950.78   Med: 24.43   Max: 970.64
Current: 9.02

During the past 13 years, the highest EV-to-EBITDA of Pacira BioSciences was 970.64. The lowest was -1950.78. And the median was 24.43.

FRA:82P's EV-to-EBITDA is ranked better than
71.23% of 709 companies
in the Drug Manufacturers industry
Industry Median: 15.03 vs FRA:82P: 9.02

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-18), Pacira BioSciences's stock price is €28.60. Pacira BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €1.339. Therefore, Pacira BioSciences's PE Ratio for today is 21.36.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Pacira BioSciences EV-to-EBITDA Historical Data

The historical data trend for Pacira BioSciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences EV-to-EBITDA Chart

Pacira BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.69 41.42 27.77 16.01 12.13

Pacira BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.00 19.65 14.63 12.13 8.61

Competitive Comparison of Pacira BioSciences's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's EV-to-EBITDA falls into.



Pacira BioSciences EV-to-EBITDA Calculation

Pacira BioSciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1555.513/173.165
=8.98

Pacira BioSciences's current Enterprise Value is €1,555.5 Mil.
Pacira BioSciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €173.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pacira BioSciences  (FRA:82P) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pacira BioSciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=28.60/1.339
=21.36

Pacira BioSciences's share price for today is €28.60.
Pacira BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.339.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Pacira BioSciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacira BioSciences (FRA:82P) Business Description

Traded in Other Exchanges
Address
5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.

Pacira BioSciences (FRA:82P) Headlines

No Headlines